Always consult your healthcare provider before beginning any new supplement
Quick reference for the subcodes: R13.10: unspecified, the common starting code R13.11: oral phase, bolus control R13.12: oropharyngeal phase, billed most often R13.13: pharyngeal phase, aspiration focus R13.14: pharyngoesophageal phase, the UES code R13.19: other, cervical and neurogenic ASHA's ICD-10 reference confirms the R13.1 series for dysphagia and flags when the I69 sequelae codes take over for post-stroke cases, which is where we're headed next
Nordexa Research avoids that approach
Cardiovascular Benefits: Beyond weight loss, patients may experience improvements in cardiovascular risk factors, such as lower blood pressure and improved lipid profiles
Overall, WA exhibits neuroprotective effects by activating the PI3K/Akt pathway, modulating the expression of MMPs, and inhibiting the migration of VSMCs [136]